Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
- Author(s)
- Jaeger, U; Tam, CS; Borchmann, P; McGuirk, JP; Johansen, M; Waller, EK; Jaglowski, S; Andreadis, C; Foley, SR; Westin, JR; Fleury, I; Ho, PJ; Mielke, S; Teshima, T; Salles, G; Schuster, SJ; He, F; Maziarz, RT; Mayer, S; Makita, S; Kersten, MJ; Ghosh, M; Wagner-Johnston, N; Kato, K; Corradini, P; Goto, H; Colicino, S; Agarwal, A; Lobetti-Bodoni, C; Bishop, MR;
- Details
- Publication Year 2022-08-23,Volume 6,Issue #16,Page 4816-4820
- Journal Title
- Blood Advances
- Publication Type
- Research article
- Keywords
- Humans; *Lymphoma, Large B-Cell, Diffuse/drug therapy/pathology; *Lymphoma, Non-Hodgkin; Receptors, Antigen, T-Cell
- Department(s)
- Haematology
- PubMed ID
- 35687492
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2021006193
- Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2021006193- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-12-18 06:40:31
Last Modified: 2024-12-18 06:41:56